NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)

Recruiting

Phase 1

NKX019NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)

Sponsor:

Nkarta, Inc.

Code:

NCT06557265

Conditions

Lupus Nephritis

Glomerulonephritis

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

NKX019

Cyclophosphamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Nkarta, Inc. on 2025-04-10.